Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99mTc-sestamibi

Journal of Nuclear Medicine

Volumn 44, Issue 8, 2003, Pages 1253-1262

  Mariani, Giuliano ^a,b   Filocamo, Mirella ^c   Giona, Fiorina ^d   Villa, Giuseppe ^e   Amendola, Angela ^d   Erba, Paola ^a   Buffoni, Ferdinando ^e   Copello, Francesco ^f   Pierini, Anna ^b   Minichilli, Fabrizio ^b   Gatti, Rosanna ^c   Brady, Roscoe O ^g  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

99mTc sestamibi; Bone marrow involvement; Disease severity; Gaucher's disease; Scintigraphic score

Indexed keywords

BIOCHEMICAL MARKER; CHITOTRIOSIDASE; ENZYME; HEMOGLOBIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; UNCLASSIFIED DRUG; ALGLUCERASE; DIAGNOSTIC AGENT; GLUCOSYLCERAMIDASE; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; BODY WEIGHT; BONE MARROW; BONE MARROW SCINTISCANNING; CELL INFILTRATION; CHILD; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG UPTAKE; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HEPATOMEGALY; HUMAN; INFORMATION PROCESSING; LEG; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL ANALYSIS; TOPOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HOSPITALIZATION; KNEE; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TECHNETIUM TC 99M SESTAMIBI;

EID: 10644293202     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Brady RO, Kanfer J, Shapiro D The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J Biol Chem. 1965;240.39-43
2. Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic and enzymological aspects. Baillières Clin Haematol. 1997;10:635-656.
3. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency: magrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324.1464-1470
4. Balmatoug N, Billette T. Skeletal response to enzyme replacement therapy of type 1 Gaucher disease: a preliminary report of the French experience. Semin Hematol. 1995;32(suppl 1):33-38.
5. Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher's disease: skeletal responses to macrophage-targeted glucocerebrosidase Pediatrics. 1995;96:629-637.
6. Rosenthal DI, Scott JA, Barranger J, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am. 1986;68:802-807.
7. Johnson LA, Hoppel DE, Gerard EL, et al. Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease Radiology. 1992;82. 451-455.
8. Hermann G, Shapiro RS, Abdelwahab IF, Grabowski G. MR imaging in adults with Gaucher disease type I evaluation of marrow involvement and disease activity. Skeletal Radiol. 1993;22:247-251.
9. States LJ Imaging of metabolic bone disease and marrow disorders in children. Radiol Clin North Am. 2001.39.749-772.
10. Lorbeiboym M, Pastores G, Kim CK, Hermann G, Glajchen N, Machac J. Scintigraphic monitoring of patients with type 1 Gaucher disease on enzyme replacement therapy. J Nucl Med. 1997,38:890-895
11. Vogler JB, Murphy WA. Bone marrow imaging Radiology. 1988;168:679-691.
12. Moulopoulos LA, Dimopoulos M Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood 1997;90 2127-2138.
13. Rademakers RP. Radiologic evaluation of Gaucher bone disease. Serum Hematol 1995;32:14-19.
14. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR 2002;179 961-965.
15. Rosenthal DI, Barton NW, McKusick KA, et al. Quantitative imaging of Gaucher disease. Radiology. 1992;185:841-845.
16. Jones AG, Abrams MJ, Davison A, et al. Biological studies on a new class of technetium complexes: the hexakis(alkylisonitrile technetium(I) cation. Int J Nucl Med Biol. 1984;11:225-232.
17. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium in cultured mouse fibroblasts. J Nucl Med. 1990;31:1646-1653.
18. Piwnica-Worms D, Holman LB. Noncardiac application of hexakis (alkyl-isomtrile) technetium-99m complexes. J Nucl Med. 1990;31:1161-1167
19. Mariani G. Unexpected keys in cell biochemistry imaging: some lessons from technetium-99m sestamibi. J Nucl Med. 1996;37.536-538.
20. 99mTc sestamibi: a new agent for parathyroid imaging. Nucl Med Commun. 1989;10:791-794.
21. Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors: preliminary results and comparison with Tl-201. Clin Nucl Med. 1992;17:171-177.
22. Khalkhali I, Mena I, Diggles I. Review of imaging techniques for the diagnosis of breast cancer, a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med. 1994;21:432-436.
23. Durie BGM, Waxman A, Jochelson M, Giles FJ, Hamburg G, Avedon M. Technetium-99m sestamibi scanning in multiple myeloma [abstract] Proc Am Soc Clin Oncol. 1994;13:411.
24. Look RM, Lim SW, Waxman A, et al. Technetium-99m sestamibi scintigraphy in multiple myeloma stem cell transplantation. Leuk Lymphoma. 1996;20:453-456.
25. Wakasugi S, Teshima H, Nakamura H, et al Tc-99m MIBI localization in bone marrow: a marker of bone marrow malignancy. Clin Nucl Med. 1998;23:664-671.
26. 99mTc-MIBI for detecting bone marrow metastases. J Nucl Med. 2002;43:596-602.
27. 99mTc-HMPAO images in Gaucher's disease. Eur J Nucl Med. 1996;23:466-470.
28. Blocklet D, Abramowicz M, Schoutens A. Bone, bone marrow, and MIBI scintigraphic findings in Gaucher's disease "bone crisis" Clin Nucl Med. 2001; 26:765-769.
29. Aharoni D, Krausz Y, Elstein D, Hadas-Halpern I, Zimran A. Tc-99m sestamibi bone marrow scintigraphy in Gaucher disease. Clin Nucl Med. 2002;27:503-509.
30. Grabowski GA. Current issues in enzyme therapy for Gaucher disease. Drugs. 1996;52:159-167.
31. Filocamo M., Mazzotti R, Stroppiano M, et al Analysis of glucocerebroside gene and mutation profile in 144 Italian Gaucher patients Hum Mutat. 2002;20:234-235.
32. Zimran A, Kay AC, Gelbart T, et al. Gaucher disease: clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 1992;71. 337-353
33. Hollak CEM, van Weely S, van Oers MHJ, et al Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-1292.
34. Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene-nature of inherited enzyme deficiency. J Biol Chem 1998;273 25680-25685.
35. Balleari E, Villa G, Garrè S, et al. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haematologica. 2001;86:78-84.
36. Elstein D, Itzchaki M, Mankin HJ. Skeletal involvement in Gaucher's disease Baillières Clin Haematol. 1997;10:793-816.
37. Dunteman GH. Principal Component Analysis. Los Angeles, CA: SAGE University Papers (Quantitative Applications in the Social Sciences, no. 69). 1989.
38. Poll LW, Koch J-A, vom Dahl S, et al. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results. Skeletal Radiol. 2001;30:496-503
39. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM. 1997;90:19-25.
40. Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet. 1996;348.1555-1559.
41. Lorberboym M, Vallabhajousula S, Lipszyc H, Pastores G. Scintigraphic evaluation of Tc-99m-low-density lipoprotein (LDL) distribution in patients with Gaucher disease. Clin Genet. 1997;52:7-11.
42. Barton NW, Ludman M, Benkov K, et al. Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher cell burden on energy requirements. Metabolism. 1989;38:1238-1243.
43. Aerts JMF, Hollak CEM. Plasma and metabolic abnormalities in Gaucher's disease. Ballières Clin Haematol. 1997;10:691-709.